Centre d’Immunologie Pierre Fabre, St-Julien en Genevois, France
Alain Beck is Senior Director, Analytical Chemistry, New Biological Entities platform and a member of CIPF’s board of Directors. He is co-inventor on 16 patents, author/co-author of more than 200 publications and is Associate Editor of mAbs. He has contributed to more than 260 scientific meetings as chairman, invited speaker, panelist, moderator, advisor, and/or organizer (mAbs, ADCs, Immunocytokines, Biobetters, Biosimilars, pAbs, BsAbs, Fc-fusions, Protein Scaffolds, Mass Spec, Med Chem, PK/PD, separative sciences) and was ranked 6 out of 50 global antibody industry influencers. He is also regularly involved in boards of biomedical & biotechnological experts, e.g. for the WHO (Vaccines & Biologics), the European Commission (7thFP), the European Pharmacopoeia (EDQM), the National Institute of Standards and Technology (NIST), and the pharma industry (MabDesign, LEEM Biotech, Immunotherapies, Biovision).
Utrecht University (and University of Georgia), Utrecht, The Netherlands (and Athens (GA), USA)
Geert-Jan Boons’ research program integrates method development for complex oligosaccharide and glycoconjugate synthesis, application of the new methods for the preparation of biologically important compounds such as tumor-associated antigens, capsular polysaccharides, lipopolysaccharides and heparan sulfates, and innovative use of the resulting compounds in biological studies. The synthetic methods developed by the Boons group are widely employed by others thereby providing much greater access to this important class of compounds. Biological studies by the Boons group have provided molecular insight into infectious and immunological processes and the importance of these studies are underscored by the fact that several compounds developed by him are entering clinic evaluation.
University of California, Davis, USA
Xi Chen’s research interests are at the interface of chemistry and biology with focus on carbohydrate chemistry and glycobiology. Her research group is trying to understand carbohydrate-related biological process in the areas of prebiotics, immunology, cancer, inflammation, and bacterial infection. Combined chemical and enzymatic synthetic approaches are used to produce and study biomedically important complex carbohydrates and glycoconjugates. Moreover, her group uses biochemistry and molecular biology tools to explore the structure-function relationship of the enzymes involved in the biosynthesis of carbohydrates and glycoconjugates.
Cornell University, Ithaca (NY), USA
Matthew P. DeLisa's research focuses on understanding and controlling the molecular mechanisms underlying protein biogenesis - folding and assembly, membrane translocation and posttranslational modifications - in the complex environment of a living cell. His contributions to science and engineering include the invention of numerous commercially important technologies for facilitating the discovery, design and manufacturing of human drugs and seminal discoveries in the areas of cellular protein folding and protein translocation. A major goal of the DeLisa group is to engineer the protein machinery of simple bacteria for solving complex problems in biology and medicine. Matthew P. DeLisa is a fellow of the American Institute for Medical and Biological Engineering.
Systems Glycobiology Research Group at RIKEN, Wako, Japan
Naoyuki Taniguchi launched the Systems Glycobiology Research Group at RIKEN, Advanced Science Institute in 2007 as the group director and now served as Group Director of Glyco-Oncology, Osaka International Cancer Institute. His work has focused on the structure and function of glycans, especially the role of N-linked glycoproteins in relation to the mechanism of the disease biomarker discovery and therapeutics. He has also worked on redox regulations including glutathione and superoxide dismutase. He has received many awards such as International Glycoconjugate Organization Award (2002) and Japan Academy Prize (2011) and Karl Meyer Lectureship Award from Society for Glycobiology (2018).
Institute for Glycomics, Griffith University, Brisbane, Australia
Mark von Itzstein is the director of the Institute for Glycomics, Griffith University. He established the Institute in 2000 as a multi-disciplinary Institute that now has approximately 200 experts and support members. Mark von Itztein is an international leader in glycoscience, particularly in the study of host glycan–pathogen interactions, and anti-infective drug discovery. He has established an internationally-recognised research program that is directed towards the discovery of novel anti-microbial drugs, including novel anti-viral drugs and anti-cancer drugs based on carbohydrate-related pathways. Professor Mark von Itzstein is a Fellow of the Australian Academy of Science and the Australian Academy of Health & Medical Sciences.